Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ELVN | CLUSTER | neutral | 2/10 | Two senior executives at Enliven Therapeutics (CMO and CFO) conducted open-market sales totaling ~$323K within a 7-day w | Sep 21, 2026 |
| TYRA | SC 13G | neutral | 4/10 | Biotechnology Value Fund (BVF) and related entities filed a Schedule 13G on September 21, 2026, disclosing a passive 6.1 | Sep 21, 2026 |
| TOMZ | 8-K | neutral | 4/10 | TOMI Environmental Solutions and Carbonium Core mutually terminated their merger agreement, effective September 15, 2026 | Sep 21, 2026 |
| ORKA | CLUSTER | bearish | 5/10 | Five Oruka Therapeutics insiders, including the CEO, COO, General Counsel, Chief Medical Officer, and SVP of Finance, ex | Sep 21, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 6/10 | TOMI Environmental Solutions and Carbonium Core have mutually terminated their June 28, 2026 merger agreement, with each | Sep 21, 2026 |
| HELP | 6-K | neutral | 3/10 | Cybin Inc., operating as Helus Pharma, presented four posters at Psych Congress 2026 covering new analyses of HLP003, it | Sep 21, 2026 |
| JAGX | 8-K | neutral | 3/10 | Jaguar Health filed a Certificate of Elimination removing 14 series of preferred stock (Series B-2 through O) from its c | Sep 21, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | A cluster of insider sales at United Therapeutics follows the company's $477.6M accelerated share repurchase agreement. | Sep 21, 2026 |
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted inducement stock options and RSUs to one new non-executive employee under its 2026 Inducemen | Sep 21, 2026 |
| BSEM | PRESS-RELEASE | neutral | 2/10 | BioStem Technologies has joined the Terminal1 platform for shareholder intelligence, investor communications, and digita | Sep 21, 2026 |
| PTCT | PRESS-RELEASE | bullish | 6/10 | PTC Therapeutics completed its acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Thera | Sep 21, 2026 |
| ANAB | PRESS-RELEASE | neutral | 5/10 | AnaptysBio reported Q2 2026 EPS of $0.07, a 50.5% miss vs consensus of $0.14, though collaboration revenue of $27.5M bea | Sep 21, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | A cluster of insider selling at Pharvaris N.V. (PHVS) has emerged over the past week, with 7 insiders including the CEO, | Sep 21, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a routine 6-K on September 21, 2026, informing exchanges that management will participate | Sep 21, 2026 |
| HOWL | SC 13G | neutral | 3/10 | Peter Moll, a private investor based in Dresden, Germany, disclosed a 5.2% passive stake in Werewolf Therapeutics via a | Sep 21, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyba | Sep 21, 2026 |
| IMNM | ANALYST-UPGRADE | bullish | 4/10 | Alliance Global Partners initiated coverage on Immunome Inc. (IMNM) with a Buy rating and a $32 price target, implying 3 | Sep 21, 2026 |
| HYFT | 6-K | neutral | 4/10 | MindWalk announced a successful production deployment of the open-source OpenFold3 model on AMD Instinct MI325X GPUs via | Sep 21, 2026 |
| GRML | PRESS-RELEASE | neutral | 5/10 | Greenland Mines applied for a new 262 km² exploration license east of its Sarfartoq project in Greenland, expanding its | Sep 21, 2026 |
| RXRX | 8-K | mixed | 5/10 | Recursion Pharmaceuticals amended its Master Agreement with Tempus AI, extending the term from five to six years and eli | Sep 21, 2026 |
| ATAI | 15-12G | neutral | 6/10 | AtaiBeckley Inc. filed Form 15-12G to terminate its SEC registration under Section 12(g), effective September 21, 2026, | Sep 21, 2026 |
| TLX | 6-K | bullish | 7/10 | Telix Pharmaceuticals announced a transformational merger with ITM Isotope Technologies Munich SE for US$1.65 billion up | Sep 21, 2026 |
| CUE | 8-K | bullish | 7/10 | Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in chronic spontaneous urticar | Sep 21, 2026 |
| HELP | PRESS-RELEASE | neutral | 4/10 | Helus Pharma presented four posters at Psych Congress 2026, including 12-month efficacy data from its Phase 1/2a study o | Sep 21, 2026 |
| ALKS | 8-K | bullish | 6/10 | Alkermes announced positive Phase 1b proof-of-concept data for ALKS 7290, a first-in-class orexin 2 receptor agonist for | Sep 21, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca announced that the EMA's CHMP has recommended Klygefa (gefurulimab) for EU approval as an add-on therapy for | Sep 21, 2026 |
| TLSA | 6-K | neutral | 4/10 | Tiziana Life Sciences announced that the last patient has completed their last visit in the Phase 2a INFORM-MS trial of | Sep 21, 2026 |
| SCNI | 6-K | neutral | 4/10 | Scinai received Nasdaq confirmation that it has regained compliance with the $1.00 minimum bid price requirement, closin | Sep 21, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca and Daiichi Sankyo's Enhertu received a positive CHMP opinion recommending EU approval as an adjuvant monoth | Sep 21, 2026 |
| ELOX | EFFECT | neutral | 5/10 | Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-298904) became effective on September 18, 2026, enabling | Sep 21, 2026 |